Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,683.00+3.69%ETH$2,436.19+6.33%GOLD$4,072.20-0.02%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
ME

NASDAQ · MENS

Jyong Biotech Ltd. Ordinary Shares

Healthcare · Biotechnology

$1.78

Down-$0.04 (-2.25%)

Updated Nov 4, 2026, 11:03 PM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.04B
P/E ratio
-813.48
Dividend yield
0.00%
52-week range
$1.50 – $3.00
Volume
90.77K
Avg. volume
352K

Price performance · MENS

MENS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

MENS closed at $1.78 after 21 trading sessions, down 11.88% for the selected period.

Last close
$1.78
Period change
-11.88%
Period low
$1.74
Period high
$2.10
Daily close
View OHLC price history
MENS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.90$1.91$1.71$1.7890.77K
Nov 2, 2026$1.91$2.02$1.80$1.8726.63K
Oct 30, 2026$1.91$1.96$1.84$1.8818.78K
Oct 29, 2026$2.01$2.09$1.87$1.8830.81K
Oct 28, 2026$1.92$2.05$1.90$2.0514.16K
Oct 27, 2026$1.84$1.9392$1.79$1.9119.86K
Oct 26, 2026$1.67$1.82$1.67$1.7733.62K
Oct 23, 2026$1.71$1.815$1.51$1.7760.02K
Oct 22, 2026$1.94$2.00$1.64$1.74130.19K
Oct 21, 2026$1.90$1.916$1.845$1.8925.57K
Oct 20, 2026$1.93$1.955$1.83$1.8627.41K
Oct 19, 2026$1.89$2.04$1.865$1.9344.82K
Oct 16, 2026$1.97$2.02$1.795$1.8441.21K
Oct 15, 2026$2.03$2.12$1.9501$1.98142.58K
Oct 14, 2026$2.06$2.119$1.97$2.0532.84K
Oct 13, 2026$2.10$2.11$1.99$2.0422.95K
Oct 12, 2026$2.148$2.148$2.02$2.1020.26K
Oct 9, 2026$2.10$2.18$2.05$2.1036.71K
Oct 8, 2026$2.06$2.12$2.00$2.1039.25K
Oct 7, 2026$2.07$2.10$2.01$2.0626.84K
Oct 6, 2026$2.05$2.188$2.02$2.0220.19K

Latest MENS news

The latest Smart Investors Daily articles mentioning MENS.

Stock researchCompany · Overview

MENS research

Overview

Company profile and research snapshot.

Company profile

Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 13, 2026

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS-8, and the concurrent attempt of its commercial footprint in key Asian markets. The Company believes the conver

defenseworld.net · Dec 8, 2025

Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th

Jyong Biotech's (NASDAQ: MENS - Get Free Report) lock-up period is set to end on Monday, December 15th. Jyong Biotech had issued 2,666,667 shares in its IPO on June 17th. The total size of the offering was $20,000,003 based on an initial share price of $7.50. Shares of the company owned by major shareholders and company

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By